Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

DISEASE CHARACTERISTICS:

Histologically confirmed renal cell carcinoma

Primary lesion or metastatic site demonstrating clear cell variant with < 25% of any other histology
Radiographically measurable disease by RECIST criteria
Initiated treatment with sunitinib malate ≤ 6 weeks ago
No radiographically detectable brain metastases by MRI or CT scan

HLA-partially matched related donor available, as determined by serologic and/or DNA typing

Appropriate HLA match (≥ 2/6 HLA A, B, DR match)

PATIENT CHARACTERISTICS:

ECOG performance status 0-1
Absolute neutrophil count > 1,500/mm³
Platelet count > 100,000/mm³
Total bilirubin ≤ 2.0 times upper limit of normal (ULN)
AST ≤ 3.0 times ULN
Calculated creatinine clearance ≥ 40 mL/min
Cardiac ejection fraction ≥ 50%
QTc interval < 500 msec by EKG
Not pregnant
Negative pregnancy test
Fertile patients must use effective contraception
No known HIV positivity

None of the following within the past 6 months:

Myocardial infarction
Severe/unstable angina
Coronary/peripheral artery bypass graft
Symptomatic congestive heart failure
Cerebrovascular accident or transient ischemic attack
Pulmonary embolism
No ongoing ventricular cardiac dysrhythmias ≥ grade 2, according to NCI CTCAE v3.0
No history of serious ventricular arrhythmia (e.g., ventricular tachycardia > 3 beats in a row)
No ongoing atrial fibrillation
No other malignancies within the past 3 years, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, or ductal or lobular carcinoma in situ of the breast
No other concurrent serious illness

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
No prior systemic therapy for metastatic renal cell carcinoma
No prior immunotherapy
No prior VEGF-targeted or mTOR-targeted therapies
No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital), St. John's wort, ketoconazole, dexamethasone, dysrhythmic drugs (e.g., terfenadine, quinidine, procainamide, sotalol, probucol, bepridil, indapamide, or flecainide), haloperidol, risperidone, rifampin, grapefruit, or grapefruit juice
No other concurrent investigational anticancer agents